Overexpression of FGFR1 in resistant to gefitinib (EGFR inhibitor) NSCLC (non-small-cell lung cancer) cells led to increased activation of AKT and mTOR, whereas FGFR1 inhibition decreased phosphorylation of both kinases and re-sensitized cells to gefitinib [54,83]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.